triptolide has been researched along with frax597 in 1 studies
| Studies (triptolide) | Trials (triptolide) | Recent Studies (post-2010) (triptolide) | Studies (frax597) | Trials (frax597) | Recent Studies (post-2010) (frax597) |
|---|---|---|---|---|---|
| 1,158 | 6 | 820 | 16 | 0 | 16 |
| Protein | Taxonomy | triptolide (IC50) | frax597 (IC50) |
|---|---|---|---|
| Serine/threonine-protein kinase PAK 3 | Homo sapiens (human) | 0.0164 | |
| Serine/threonine-protein kinase PAK 4 | Homo sapiens (human) | 0.0133 | |
| Serine/threonine-protein kinase PAK 1 | Homo sapiens (human) | 0.0219 | |
| Serine/threonine-protein kinase PAK 2 | Homo sapiens (human) | 0.0143 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, MR; Maruta, H | 1 |
1 review(s) available for triptolide and frax597
| Article | Year |
|---|---|
From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
Topics: Animals; Antineoplastic Agents; Click Chemistry; Drug Discovery; Humans; Longevity; Neoplasms; p21-Activated Kinases; Protein Kinase Inhibitors | 2017 |